The Medical Devices sector report, “Structural Heart Occluders Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the Structural Heart Occluders pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Structural heart occluders are used for treatment congenital heart defects by closing openings in the heart. Structural heart occluders covers left atrial appendage closure devices, atrial septal defect occluders, ventricular septal defect occluders, patent foramen ovale closure devices, patent ductus arteriosus closure devices.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Structural heart occluders are used for treatment congenital heart defects by closing openings in the heart. Structural heart occluders covers left atrial appendage closure devices, atrial septal defect occluders, ventricular septal defect occluders, patent foramen ovale closure devices, patent ductus arteriosus closure devices.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Structural Heart Occluders under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Structural Heart Occluders and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Structural Heart Occluders under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Structural Heart Occluders - Pipeline Products under Development by Companies
5 Structural Heart Occluders Companies and Product Overview
6 Structural Heart Occluders- Recent Developments
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Japan Co Ltd
- Aegis Medical Innovations Inc.
- Aporo Biomedical Inc. (Inactive)
- Append Medical
- atHeart Medical
- AuriGen Medical Ltd
- Boston Scientific Corp
- CARAG AG
- Cierra Inc. (Inactive)
- Conformal Medical Inc
- Cor Habere Corp
- Dextera Surgical Inc
- Endomimetics LLC
- Ension Inc.
- Guangdong Pulse Medical Technology Co Ltd
- Hangzhou Dinova EP Technology Co Ltd
- Hansen Medical Inc (Inactive)
- Jenscare Scientific Co Ltd
- Laminar Inc
- Lepu Scientech Medical Technology (Shanghai) Co Ltd
- Lifetech Scientific (Shenzhen) Co Ltd
- LuSeed Vascular
- Mayo Clinic
- Medtronic Plc
- Micro Interventional Devices Inc.
- Northwestern University
- Occlutech International AB
- SentreHEART Inc
- SeptRx Inc. (Inactive)
- Shanghai Shenqi Medical Technology Co Ltd
- Swissimplant AG
- The Chaim Sheba Medical Center
- University of Minnesota
- Vascular Closure Systems Inc
- Vascular Concepts Ltd
- W. L. Gore & Associates Inc
- Worry Free Beating
